←
Stephane Angers4,733 posts
Stephane Angers avatar

Stephane Angers

@StephAngers

Director Donnelly Centre for Cellular and Biomolecular Research, and Professor at the University of Toronto, Founder AntlerA Therapeutics,

◷ Joined February 2009▧ 109 Photos and videos
Donnelly Centre avatar
⟳ Stephane Angers retweeted
Donnelly Centre@DonnellyCentre·Nov 17

🔎💻 Donnelly researchers from @garybader1's lab have developed DeepLineage, a deep-learning method that outperforms existing approaches in predicting cell fate by learning from gene expression and lineage histories over time. thedonnellycentre.utoronto.c…

0:23
Donnelly Centre avatar
⟳ Stephane Angers retweeted
Donnelly Centre@DonnellyCentre·Oct 29

🧠 What if we could help the brain heal after a stroke? This #WorldStrokeDay, Donnelly researchers are advancing a new approach to stroke recovery, combining enzyme and cell therapies to support brain repair in experimental models of stroke. 🔗thedonnellycentre.utoronto.c…

Donnelly Centre avatar
⟳ Stephane Angers retweeted
Donnelly Centre@DonnellyCentre·Oct 15

Donnelly Centre researchers, together with an international team of collaborators, identified hundreds of new microexons and developed a #machinelearning approach that could uncover hidden clues in the #genetics of #Autism. Read the @Nature study: nature.com/articles/s41586-0…

American Academy of Ophthalmology avatar
⟳ Stephane Angers retweeted
American Academy of Ophthalmology@aao_ophth·Oct 11

What could retinal treatment look like five years from now? At AAO 2026 Retina Subspecialty Day, Drs. Charles Wykoff, Donald D'Amico, and Ehsan Rahimy discussed emerging approaches to retinal disease, from investigational agents including tarcocimab, tabirafusp, and remigromig, to the PRIMA photovoltaic subretinal implant for end-stage geographic atrophy. Watch the video for the outlook. For more, visit aao.org/2026. #aao2026 #retina #aao #retina

2:05
Donnelly Centre avatar
⟳ Stephane Angers retweeted
Donnelly Centre@DonnellyCentre·Sep 25

🔬Join our interdisciplinary research community and help advance discovery, medicine, and human health! Recent PhD graduates have until Nov. 3 to apply for the Charles H. Best Postdoctoral Fellowship at #UofT's Donnelly Centre, offering $60K for one year: tinyurl.com/4rv5jdxt

Post attachment
Stephane Angers avatar
Stephane Angers@StephAngers·Sep 24

4/4 Full year-one results come at #AAO2026 on Oct 10, and the BAROLO (DME) and SUPER TUSCAN (nAMD/RVO) trials are ongoing. Grateful to the trainees, collaborators and patients behind this.

Stephane Angers avatar
Stephane Angers@StephAngers·Sep 24

3/4 New mechanism: instead of blocking VEGF, it activates Wnt to repair the blood–retinal barrier. It traces back to our work at @UofT on engineering Wnt-activating antibodies (pubmed.ncbi.nlm.nih.gov/3145…) (pubmed.ncbi.nlm.nih.gov/3410…), then went through AntlerA, EyeBio and Merck.

Stephane Angers avatar
Stephane Angers@StephAngers·Sep 24

2/4 Both doses were non-inferior to ranibizumab in best-corrected visual acuity at week 52. The randomized, double-masked trial enrolled 984 patients.

Stephane Angers avatar
Stephane Angers@StephAngers·Sep 24

1/4 Today Merck reported that remigromig (MK-3000, formerly EYE103), a tri-specific Wnt agonist antibody, met its primary endpoint in the pivotal ph. 3 BRUNELLO trial in diabetic macular edema merck.com/news/mercks-remigr…

Biotech Investor avatar
⟳ Stephane Angers retweeted
Biotech Investor@BioInvest_MD·Sep 24

$MRK's WNT with positive Ph3 data in DME. This is significant as its the first non-VEGF MONOTHERAPY to show success in retina, after steroids. Nice readthrough for $SRZN as its next up with a VEGF/WNT bispecific. merck.com/news/mercks-remigr…

Would $MRK be hiring a US sales leader if they knew that Brunello failed? Data is scheduled to be presented next month at AAO, seems very bullish for $SRZN

Post attachment
Anthropic avatar
⟳ Stephane Angers retweeted
Anthropic@AnthropicAI·Aug 18

Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work. We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets. We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.

0:11